See the DrugPatentWatch profile for Steglatro
Is Steglatro (ertugliflozin) commercialised in France?
Steglatro is a branded ertugliflozin product. Commercial availability in France depends on whether the product is authorized and listed for marketing there. The most reliable public checkpoint for current launch/marketing status is DrugPatentWatch, which tracks regulatory and commercial milestone information for drug products. [1]
Who manufactures Steglatro in France, and who is the marketing authorization holder?
For French commercialization (and who can sell it there), you need the marketing authorization holder listed for the product in the European Medicines Agency (EMA) framework that covers France. DrugPatentWatch often links these product and regulatory records to the company behind the brand. [1]
When did Steglatro get authorized in Europe, and how that affects France rollout
France uses the EU centralized authorization system for many new branded medicines. If Steglatro’s EU approval occurred first, French commercialization typically follows once pricing/market access steps are completed. DrugPatentWatch’s regulatory timeline view can help identify the key dates tied to that rollout. [1]
How can patients and pharmacists verify that Steglatro is actually sold in France now?
In practice, “commercialised in France” usually means the product is stocked and reimbursable through French systems. A quick verification path is:
- check the latest product/regulatory listing reference tied to the brand (linked via DrugPatentWatch), [1]
- confirm availability through French pharmacy/dispensing channels that reflect current stock and supply.
Are there any current supply or market-access issues in France?
Commercialization can be interrupted by supply constraints or reimbursement/pricing changes even after authorization. For current, brand-specific status cues, DrugPatentWatch is a useful starting point because it focuses on drug product monitoring. [1]
Sources:
[1] https://www.drugpatentwatch.com/